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Abstract.  A  single enzyme found in both Drosophila 
and mammalian  cells is able to selectively bind and 
degrade transforming growth factor (TGF)-alpha and 
insulin,  but not EGF, at physiological concentrations. 
These growth factors are also able to inhibit binding 
and degradation of one another by the enzyme. Al- 
though there are significant immunological differences 
between the mammalian  and Drosophila enzymes, the 
substrate specificity has been highly conserved.  These 
results demonstrate the existence of a selective TGF- 
alpha-degrading  enzyme in both Drosophila and mam- 
malian cells. The evolutionary conservation of the 
ability to degrade both insulin and TGF-alpha suggests 
that this property is important  for the physiological 
role of the enzyme and its potential for regulating 
growth factor levels. 
ROWTH factors play an important  role in cell growth 
and transformation.  Accordingly, the areas of growth 
factor  synthesis,  receptor  interactions,  and  signal 
transduction  have been intensively studied.  In contrast, with 
the exception of insulin,  little is known about the important 
area of growth factor degradation  and its role in the regula- 
tion of growth and transformation. 
Transforming  growth factor (TGF)~-alpha  is a  polypep- 
tide secreted by a variety of transformed cells that can induce 
reversible phenotypic transformation  of normal mammalian 
cells in culture and is closely related  structurally  to EGF (3, 
4, 20, 26, 29). Like EGF, TGF-alpha binds to the EGF recep- 
tor, leading to activation  of the receptor tyrosine kinase and 
mitogenic  stimulation.  No receptor specific for TGF-alpha 
has been identified.  Although  EGF appears to be degraded 
through  a series of proteolytic cleavages upon binding  and 
internalization  but before removal to the lysosomes (19), the 
enzymes responsible have not been isolated.  Less is known 
about the degradation  of TGF-alpha.  By contrast, the insu- 
lin-degrading  enzyme ODE) has been well characterized  as 
the enzyme responsible for initiating  insulin degradation  in 
mammalian cells (5,  12, 23). 
One approach that can yield new and relevant insights into 
the mechanism of action of mammalian  growth regulatory 
proteins is the identification  and characterization  of homo- 
logues of these proteins in lower organisms.  Recent work in 
our laboratory has led to the identification and purification of 
a growth factor-specific degrading enzyme from Drosophila 
with properties strikingly  similar to those of the mammalian 
IDE (9). The human IDE has recently been cloned and ap- 
pears to have some homology in limited regions to an Esche- 
I. Abbreviations used in this paper: IDE, insulin-degrading enzyme; TGE 
transforming growth factor. 
richia colt protease (1). Because of their similarities  and the 
fact  that  both  the  mammalian  and  Drosophila enzymes 
cleave porcine insulin at the same major sites (5, 6,  12), we 
have termed our protein the Drosophila IDE. Furthermore, 
antigenic,  physical,  and kinetic  properties indicate  that the 
Drosophila IDE is  identical  to a previously characterized 
Drosophila growth factor-binding protein (8, 28). This Dro- 
sophila protein was shown to bind mammalian  TGF-alpha, 
insulin,  and EGF with high affinity (Ka of r~10-9,  10  -7, and 
10  -6 M,  respectively)  and specificity  (8, 28).  In this com- 
munication  we demonstrate that (a) TGF-alpha,  like insulin, 
is degraded by both Drosophila and mammalian  IDE;  (b) 
both enzymes bind EGF but neither one is able to degrade 
it under our experimental  conditions;  and (c) exposure to an 
excess of one of the growth factors  inhibits  IDE-mediated 
degradation.  These results  raise  the possibility of a  func- 
tional  or  structural  relationship  between the  insulin  and 
TGF-alpha  families  that  could have profound implications 
for the coordination  of different growth-signaling  pathways. 
Materials and Methods 
Materials and Cells 
The Drosophila  Kc cells, obtained from the Cell Culture Center (Mas- 
sachusetts Institute of Technology, Cambridge, MA) were grown at 25°C 
in D22 medium supplemented with yeast hydrolysate. Insulin and EGF were 
purchased from Biomedical Technologies, Inc. (Stoneham, MA). The mono- 
iodinated 125I-insulin and 125I-EGF used for degradation assays were pur- 
chased from New England Nuclear (Boston, MA). The recombinant TGF- 
alpha was a girl from Dr. Rik Derynck (Genentech, Inc., South San Fran- 
cisco, CA), and the synthetic TGF-alpha was a girl from Dr. James Tam 
(Rockefeller University, New York).  Synthetic TGF-a|pha was used in all 
experiments, except for the affinity labeling (Fig. 3) and the inhibition of 
insulin degradation (Fig. 5) in which the recombinant TGF-alpha was used. 
Enzymobeads were from Bio-Rad Laboratories (Rockville Centre, NY). In- 
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and recombinant TGF-alpha, were iodinated using enzymobeads as previ- 
ously described (28) (final specific activity ,x,100 t~Ci/#g).  The anti-human 
EGF receptor antiserum was described previously (2). 
TCA Precipitation Degradation Assay 
Aliquots of purified IDE were diluted into a buffer containing 50 nM insulin, 
0.5 mg/ml BSA, 100 mM phosphate, pH 7.2, and 25,000 cpm of monoiodi- 
nated insulin (specific activity 80-120 #Ci//~g).  The samples were incubated 
for 15 min at 37°C and the incubation was stopped by the addition of cold 
25 % TCA• The relative amount of released radioactivity in the soluble frac- 
tion was determined as previously described (9).  For 125I-TGF-alpha and 
1251-EGF degradation assays, unlabeled insulin was omitted. The extent of 
specific degradation was evaluated by adding an excess of unlabeled insulin 
to parallel samples. All concentrations were chosen so that the extent of in- 
sulin degradation was linear with time and protein. Competition assays in 
the presence of EGF and their analyses were carded out as described (9, 10). 
Binding to the EGF Receptor 
~251-EGF or t25I-TGF-alpha  was incubated with the IDE as above and the 
samples were removed at various times. Reactions were stopped by adding 
excess insulin or by two cycles of freezing and thawing. Samples were then 
assayed for binding to the EGF receptor as described (7). 
Purification of the Drosophila and Rat Liver IDEs 
The Drosophila IDE was purified and assayed as described (9, 10). The rat 
liver IDE was isolated as described for the Drosophila IDE (9), except that 
the hydroxyl apatite column step was replaced by a second DEAE Sephadex 
column and the butyl agarose and chromatofocusing columns were omitted. 
This partially purified preparation of rat liver enzyme is equivalent to that 
used for characterization of the properties of the Drosophila and rat liver 
IDEs (9, 24). 1 #1 of  enzyme (either Drosophila  or rat liver enzyme prepara- 
tions) yielded 10% degradation of 0.1 nM J25I-labeled insulin in 10 min by 
the TCA precipitation assay. Unless indicated otherwise, all degradation as- 
says were performed with 2 t~l of enzyme in a final volume of 50 #l/sample. 
Affinity Labeling 
Both rat  liver and Drosophila IDE (15  and 5  tzl,  respectively) were in- 
cubated on ice with radiolabeled ligand (•10 -9 M) in the absence or pres- 
ence of insulin (10  -5 M) or EGF (10  -5 M) in a final volume of 50 #l PBS 
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Figure 1. Degradation of TGF-alpha by the Drosophila and mammalian IDEs.  ~2SI-TGF-alpha (10  -9 M) was incubated with the Drosophila 
IDE (A and B) or the rat liver IDE (C and D) for the indicated times in the absence (0) or presence (o) of unlabeled insulin (10  -5 M). 
The extent of degradation was assayed by TCA precipitation (,4 and C) or TGF-alpha receptor binding (B and D).  Nonspecific counts per 
minute determined in the presence of unlabeled EGF (7.5  x  10  -7 M) were subtracted from the final values in the EGF receptor-binding 
assay•  Values represent the mean of three determinations  +  SD.  The standard deviations in B  are smaller than the symbols. 
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Figure  2.  The rat liver IDE does not degrade  labeled EGE  ~25I- 
EGF (1 nM) was incubated with the rat liver IDE for the indicated 
times and assayed for EGF degradation by the EGF-binding assay 
as in Fig.  1. Nonspecific counts per minute determined in the pres- 
ence of unlabeled EGF (7.5  x  10  -7 M) were subtracted  from the 
final values in the EGF receptor-binding assay. Values represent the 
mean of three determinations  +  SD. 
for 2 h. At this time, samples were cross-linked with dimethyl suberimidate, 
separated from labeled BSA, and autoradiographed as described (8,  28). 
Preparation of the Polyclonal Anti-Drosophila 
IDE Antiserum 
Partially purified Drosophila  IDE (80-120/~g) was loaded to a preparative 
6.5%  polyacrylamide gel under denaturing conditions as previously de- 
scribed (9). Proteins were visualized by staining with Coomassie blue. The 
ll0,000-D  protein  band  was  excised, ground,  and  injected directly  in- 
traperitoneally into New Zealand rabbits at days 1, 21, 35, 51, and 122.  Se- 
rum samples were obtained at day 1 before the first immunization (control 
serum) and at days 28, 43, 56, and 128. Antibodies specifically reactive with 
the Drosophila  IDE were detected after the second immunization. 
Immunoblotting Analysis 
Protein samples (60 /xl of enzyme) were separated by PAGE using 6.5% 
polyacrylamide gels under reducing conditions (8). The samples were then 
electrophoretically transferred from the gel to a nitrocellulose paper and the 
paper  was  probed  with  rabbit  polyclonal  antibodies (1:100 dilution)  or 
mouse monoclonal antibodies (10 ~g/ml) as described (10, 28). 
mammalian  IDE  for TGF-alpha degradation by the  same 
methods used to characterize the Drosophila enzyme. The 
data presented in Fig.  1,  C and D,  indicate that the mam- 
malian IDE is also capable of degrading TGF-alpha. As in 
the case of the Drosophila enzyme, TGF-alpha degradation 
could be inhibited by an excess of unlabeled insulin. The ex- 
tent of TGF-alpha degradation at mammalian physiological 
concentrations  was  also  very  similar  for  both  enzymes. 
These results reveal the existence of a single enzyme, both 
in Drosophila and mammals,  that is capable of degrading 
TGF-alpha and insulin. 
Despite the similarity of EGF and TGF-alpha in terms of 
structural  homology and receptor recognition, neither the 
Drosophila nor the manunalian enzyme was able to degrade 
EGF under the same experimental conditions. Although sev- 
eral lines of evidence have shown that the Drosophila IDE 
can bind EGF (8,  10, 28), no degradation of EGF was de- 
tected by either the TCA precipitation or receptor-binding as- 
says (10).  The mammalian IDE was similarly unable to de- 
grade EGF, as shown by the receptor-binding assay (Fig. 2) 
and TCA precipitation (data not shown). This result serves 
to illustrate the selectivity of the enzymatic activity for TGF- 
alpha and insulin but not EGF, a property of the enzyme con- 
served through evolution. 
To examine if the homology between the Drosophila and 
mammalian enzymes extends to binding properties, we de- 
termined whether the rat liver IDE, like the Drosophila IDE, 
could be affinity labeled with either ~2q-EGF or  ~2q-TGF- 
alpha. As shown in Fig. 3, when ~5I-labeled growth factors 
were bound and cross-linked to the mammalian IDE, only 
insulin and TGF-alpha were able to affinity label the enzyme. 
Results 
We  have  recently demonstrated  that  the Drosophila IDE 
hinds TGF-alpha with higher affinity than insulin (8, 10, 28). 
Because of this  interaction,  we determined whether TGF- 
alpha could be a  substrate for the enzyme.  The extent of 
degradation was measured by TCA precipitation or receptor 
binding of undegraded TGF-alpha. As shown in Fig. 1, A and 
B,  the results indicate that the Drosophila IDE is able to 
degrade human  t25I-TGF-alpha  at a  physiological (10  -~ M) 
concentration and that TGF-alpha degradation is specifically 
inhibited by an excess of unlabeled insulin. 
In contrast to the Drosophila homologue, the mammalian 
IDE has been characterized primarily as a degrading enzyme 
for insulin and related factors. We therefore examined the 
Figure  3. Affinity  labeling of  the rat liver IDE with insulin and TGF- 
alpha.  The rat  liver IDE  was  incubated with  125I-insulin (lanes 
1-3), 12q-EGF (lanes 4-6), or 12q-TGF-alpha (lanes 7-9) in the 
absence (lanes 1, 4, and 7) or presence of 10  -5 M unlabeled insu- 
lin (lanes 2, 5, and 8) or EGF (lanes 3, 6, and 9). For comparison, 
the Drosophila IDE affinity labeled with  z2SI-TGF-alpha is also 
shown in the absence (lane 10) or presence (lane//) of unlabeled 
insulin. 
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The greater labeling with insulin than with TGF-alpha may 
reflect higher efficiency of cross-linking since the affinities 
of recombinant TGF-alpha and insulin for the enzyme are ap- 
proximately equal (see below).  Unlike the Drosophila en- 
zyme, the rat liver enzyme could not be labeled with EGF 
under our experimental conditions.  However, there is evi- 
dence to indicate that EGF does bind weakly to the mam- 
malian enzyme. High concentrations of unlabeled EGF par- 
tially inhibited affinity labeling by t25I-TGF-alpha (Fig.  3). 
Unlabeled insulin had a more potent inhibitory effect, sug- 
gesting that the mammalian enzyme has a higher affinity for 
insulin than EGF. This is in agreement with our observations 
for the Drosophila IDE (8,  28). 
Previous work with the Drosophila enzyme showed that 
EGF inhibited  IDE-mediated insulin  degradation  (10).  To 
test if this inhibition  is also a  property of the mammalian 
IDE,  the  enzyme  was  incubated  with  ~25I-insulin in  the 
presence of unlabeled insulin and EGE Time course studies 
(Fig. 4) indicated that degradation of ~25I-insulin can be in- 
hibited by EGF and insulin.  In experiments using recom- 
binant TGF-alpha, the relative potency of inhibition of '251- 
insulin degradation by the rat liver enzyme was TGF-alpha 
=  insulin >  EGF (Fig.  5).  As shown, similar results were 
obtained with the Drosophila IDE, further establishing the 
evolutionary conservation of the enzyme with respect to sub- 
strate recognition. In previous experiments (8), Drosophila 
IDE bound synthetic TGF-alpha more tightly than insulin. 
Direct comparison of synthetic with recombinant TGF-alpha 
using both IDEs showed the synthetic to be a more potent in- 
hibitor than the recombinant by at least one order of magni- 
tude (data not shown), but the limited availability of the syn- 
thetic  form precluded  its use  in comprehensive inhibition 
studies. 
Although most of the IDE properties have been conserved 
through evolution (9), including limited homology between 
the human IDE and bacterial protease (1), there are signif- 
icant  immunological  differences  between  the  mammalian 
and Drosophila IDE.  Immunoblotting (Fig.  6)  revealed a 
single band for the Drosophila IDE when blots were probed 
with either anti-Drosophila IDE (10) or anti-human  EGF 
receptor antiserum (2). A  single band for the rat liver IDE 
was observed when blots were probed with a monoclonal an- 
tibody (23) that recognized both the human and rat IDE. The 
two enzymes differed slightly in molecular weight. However, 
the antiserum specific for the Drosophila IDE and the anti- 
human EGF receptor antiserum showed no apparent immu- 
nological cross-reactivity with the mammalian IDE. Simi- 
larly,  the anti-human IDE antibodies failed to cross react 
with the Drosophila IDE. These results indicate that certain 
immunodominant epitopes of the two enzymes have not been 
conserved. 
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Figure 5. Competitive inhibition of ~251-insulin hydrolysis by unla- 
beled insulin, TGF-alpha, and EGE Drosophila (A) and rat liver 
(B) IDEs were incubated with 0.1 nM  ~25I-insulin (,~300/zCi//~g) 
and the  indicated concentrations  of unlabeled  insulin (t2), TGF- 
alpha (zx), or EGF (o). After 10 min, reactions were terminated by 
the  addition  of TCA and  assayed as described  in Materials  and 
Methods. The enzyme aliquots used had an activity of 0.1 pmol/min 
in insulin-degradation assays containing 50 nM insulin. Hydrolysis 
of ~25I-insulin at each concentration is expressed as a percentage of 
that obtained in the absence of added growth factors. Maximum hy- 
drolysis was "-,30% of total labeled insulin. These results reflect the 
mean of two determinations  +  SD. 
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liver and Drosophila IDEs. Rat 
liver IDE (lanes 1 and 3-5) and 
Drosophila IDE (lanes 6--8 and 
10) were probed with preimmune 
(lanes I and 10), anti-Drosophila 
IDE (lanes 3 and 6), anti-human 
EGF  receptor (lanes 4  and  7), 
and anti-human IDE (lanes 5 and 
8)  serum.  A  faint band  corre- 
sponding to the Drosophila IDE 
in  lane  7 is  not  visible in  the 
photograph. Prestained  molecular 
weight markers are shown  in lanes 
2 and 9. 
Discussion 
Although the biochemical properties of the mammalian IDE 
have been studied extensively, the enzyme has been charac- 
terized primarily as a specific degrading enzyme for insulin 
and insulin-related factors (5, 25).  We now report a  novel 
property of the mammalian enzyme-  the ability to bind and 
degrade TGF-alpha. This observation reveals a new, growth 
factor-related class of substrates for the enzyme that could 
certainly affect  the physiological function. Information  about 
nonlysosomal growth  factor degradation and  its potential 
role in growth regulation is very limited at present, and these 
results represent the first description of a nonlysosomal en- 
zyme that selectively binds and degrades TGF-alpha. 
As a degrading enzyme, the IDE has an unusual substrate 
specificity. Results of the analysis of insulin cleavage suggest 
that both the Drosophila enzyme and its mammalian coun- 
terpart  display  conformational  rather  than  peptide  bond 
specificity (5, 6). The Drosophila enzyme cleaves a subset 
of the insulin bonds that are cleaved by the mammalian IDE 
(5, 6), a further indication of the evolutionary conservation 
of the enzyme's substrate specificity. We have also demon- 
strated previously (8) that the Drosophila enzyme binds and 
cross-links to insulin and EGF-related factors, but not to 
TGF-beta, PDGF, nerve growth factor, adrenocorticotropic 
hormone,  or  parathyroid  hormone.  Thus,  the  IDE  has 
limited specificity for certain hormones and growth factors. 
Previous studies from our laboratory have demonstrated 
that the Drosophila IDE is able to bind both EGF and TGF- 
alpha, although the affinities differ by at least two orders of 
magnitude (8, 28). However, we have not detected significant 
cleavage of EGF by the Drosophila enzyme even at higher 
EGF concentrations, whereas cleavage of insulin is obtained 
at nanomolar concentrations and the K~ of insulin (,,~10  -7 
M) is only 10-fold lower than that of EGF (8).  In contrast 
to the Drosophila enzyme, the mammalian IDE homologue 
does not detectably bind EGE Therefore, it was striking that 
the mammalian IDE shares with the Drosophila homologue 
the ability not only to bind but also to degrade TGF-alpha. 
The IDE represents the first example of an evolutionarily 
conserved protein with a characterized function that is able 
to discriminate between EGF and TGF-alpha. In general, the 
affinities of TGF-alpha and EGF for the EGF receptor are 
comparable (8, 28). One exception appears to be the chicken 
EGF  receptor  which binds  EGF with lower affinity than 
TGF-alpha (15). Since no distinct receptor for TGF-alpha has 
been identified, it is widely assumed that TGF-alpha elicits 
biological responses through activation of the EGF receptor 
(16). However, there are several reports indicating that TGF- 
alpha is more potent than EGF in stimulating a number of 
physiological responses.  These effects,  which include cal- 
cium mobilization (13), wound healing in skin (22), angio- 
genesis (21), and cell ruffling (18), are difficult to explain on 
the basis of EGF receptor interactions alone. Separate degra- 
dative pathways for EGF and TGF-alpha provide a possible 
mechanism  for  the  differential effects of the  two  growth 
factors. 
The physiological counterpart of TGF-alpha degradation 
by the Drosophila IDE is not presently clear. To date, no 
homologues of TGF-alpha or EGF have been identified in 
Drosophila, although two genes with EGF/TGF-alpha-like 
domains termed Notch (30) and Delta (14) have been charac- 
terized and a TGF-beta homologue has been identified (11). 
An insulin-like activity in Drosophila has also been reported 
(17). Whether the products of these Drosophila genes are 
substrates for the Drosophila IDE remains to be determined. 
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Mammalian and Drosophila IDE 
Mammalian IDE  Drosophila  IDE 
Growth  factor degradation* 
TGF-alpha  +  + 
Insulin  +  + 
EGF  -  - 
Inhibition of insulin or TGF- 
alpha degradation* 
TGF-alpha  +  + 
Insulin  +  + 
EGF  +  + 
Affinity labeling~ 
~2SI-TGF-alpha  +  + 
~25I-Insulin  +  + 
125I_EG  F  -  + 
Inhibition of TGF-alpha or 
insulin binding~ 
TGF-alpha  +  + 
Insulin  +  + 
EGF  +  + 
Immunologic cross-reactivityll 
Anti-human IDE  +  - 
Anti-Drosophila  IDE  -  + 
Anti-human EGF  receptor  -  + 
* Fig.  1 and references 5, 9,  12, 23, 27. 
* Figs.  1, 4, and 5 and references 9,  10, 24, 25. 
§ Fig. 3 and references 8-10, 24, 28. 
U  Fig. 6 and references 8,  10, 27, 28. 
Cleavage of TGF-alpha and insulin by the mammalian en- 
zyme represents  a  more  physiologically relevant  system. 
Duckworth et al.  and Hamel et al. have recently demon- 
strated that the mammalian enzyme has access to insulin in 
preacidic endosomal vesicles and appears to account for the 
majority of initial insulin degradation in hepatocytes (5, 12). 
Since the EGF receptor and the insulin receptor are both in- 
ternalized by similar receptor-mediated endocytic mecha- 
nisms, these observations suggest that the IDE may be acces- 
sible to TGF-alpha as well as insulin in the mammalian cell. 
The fact that the IDE degrades factors that regulate growth 
raises  the  possibility that the  enzyme might also  play a 
regulatory role. We have recently demonstrated that the IDE 
is developmentally regulated in Drosophila (27), suggesting 
that the enzyme may act at a rate-limiting step and is either 
detrimental during periods of rapid growth or only required 
during later stages of differentiation. The novel properties of 
the highly conserved IDE (summarized in Table I) raise in- 
teresting possibilities regarding its potential function as a 
selective growth factor-degrading enzyme in the cell. 
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